Table 1.
Therapeutic course, immunohistochemistry, pathology, and FIGO-stage.
| Pt | Age | 1st Line |
2nd Line | 3rd Line | 4th Line | 5th Line | Rec 1. No 2. Yes |
OS (mo) | Survival 1. Dead 2. Alive |
FIGO | KI-67 1. >60% 2. ≤60% |
PDL1 +≥1 −<1 |
p53 1. wt 2. mut |
P16 +/− |
Pathology |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 56 | CC/PL | 1 | 13 | 2 | II | 1 | + | 1 | + | KSCC | ||||
| 2 | 61 | CC/PL | 1 | 25 | 2 | I | 1 | + | 1 | + | NKSCC | ||||
| 3 | 62 | PC/PL | 1 | 26 | 2 | I | 2 | + | 2 | + | KSCC | ||||
| 4 | 87 | PC/SEN | 1 | 24 | 2 | I | 1 | + | 1 | + | NKSCC | ||||
| 5 | 64 | RHPC/PL | 1 | 48 | 2 | I | 2 | + | 1 | + | NKSCC | ||||
| 6 | 81 | PS | 1 | 3 | 1 | IV | 2 | + | 1 | + | KSCC | ||||
| 7 | 47 | PE | 1 | 156 | 2 | II | 1 | − | 2 | + | NKSCC | ||||
| 8 | 53 | PE | 1 | 108 | 2 | IV | 2 | + | 1 | + | ASCC | ||||
| 9 | 72 | PE | 1 | 4 | 2 | IV | 2 | + | 1 | − | KSCC | ||||
| 10 | 66 | PE | 1 | 12 | 2 | II | 2 | + | 1 | − | CCAC | ||||
| 11 | 87 | PE | 1 | 17 | 2 | II | 2 | − | 1 | + | KSCC | ||||
| 12 | 78 | PE | 1 | 4 | 1 | II | 2 | + | 2 | − | KSCC | ||||
| 13 | PE | IL->RT | HC-> GOG240 |
2 | 68 | 2 | II | 2 | + | 1 | + | KSCC | |||
| 14 | 71 | PE | CARB | 2 | 14 | 1 | IV | 2 | + | 1 | + | NKSCC | |||
| 15 | 68 | PE | IL | 2 | 12 | 1 | III | 2 | − | 2 | − | NKSCC | |||
| 16 | 65 | PE | 2 | 9 | 1 | IV | 2 | + | 2 | + | NKSCC | ||||
| 17 | 72 | CC/PL | 2 | 96 | I | 2 | + | 1 | + | NKSCC | |||||
| 18 | 32 | RHPC/PL ->CCRT |
CIS/PAC | PE | 2 | 17 | 1 | II | 1 | + | 1 | + | KSCC | ||
| 19 | 51 | GOG240 | CIS | PAC/TRA | TD-M1 | PEM/RT | 2 | 48 | 2 | IV | 2 | + | 2 | + | CCAC |
| 20 | 75 | CCRT | 2 | 7 | 1 | II | 1 | + | 2 | − | NKSCC | ||||
| 21 | 52 | CCRT | TACP | 2 | 18 | 1 | III | 2 | + | 2 | + | KSCC | |||
| 22 | 49 | CCRT | PE | RT | PS | 2 | 38 | 1 | III | 2 | + | 2 | + | KSCC |
Pt: patient; Rec: recurrence; OS: survival in months; PDL1: PD-L1 CPS score; PC/SEN: partial colpectomy + sentinel lymph node dissection; PE: pelvic exenteration; RT: radiotherapy, CCRT: concurrent chemoradiotherapy; RHPC/PL: radical hysterectomy + partial colpectomy + pelvic lymph node dissection; PC/PLNE: partial colpectomy + pelvic lymph node dissection; CC/PLNE: complete colpectomy + pelvic lymph node dissection; IL: ingunial lymph node dissection; GOG 240: 6× carboplatin/paclitaxel/bevacizumab-> becavizumab; CIS: cisplatin; CARB: carboplatin; PAC/TRA: paclitaxel weekly + trastuzumab; PEM: pembrolizumab; PS: palliative surgery (entero- and urostoma); HC: hemicolectomy; TACP: transarterial chemoperfusion with gemcitabine; KSCC: keratinizing squamous cell cancer; NKSCC: non keratinizing squamous cell cancer; ASCC: adenosquamous cell cancer; CCAC: clear cell adenocarcinoma; + deceased.